Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
- 17 August 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (7) , 700-705
- https://doi.org/10.1161/01.cir.100.7.700
Abstract
Background—Administration of protease inhibitors (PIs) to HIV-infected individuals has been associated with hyperlipidemia. In this study, we characterized the lipoprotein profile in subjects recei...Keywords
This publication has 15 references indexed in Scilit:
- Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalitiesThe Lancet, 1998
- “Buffalo hump” in HIV-1 infectionThe Lancet, 1998
- Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistanceThe Lancet, 1998
- Vascular complications associated with use of HIV protease inhibitorsThe Lancet, 1998
- Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre studyBMJ, 1997
- Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine.Journal of Clinical Investigation, 1996
- Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged menThe American Journal of Cardiology, 1996
- The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristicsInternational Journal of Public Health, 1994
- Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.Journal of Clinical Investigation, 1992
- The Mysteries Of Lipoprotein(a)Science, 1989